Related Experiment Video
Updated: Dec 26, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Host-directed therapies targeting the tuberculosis granuloma stroma
Elinor Hortle1,2, Stefan H Oehlers1,2
1Tuberculosis Research Program at the Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia.
Host-directed therapies (HDTs) target granuloma stroma to combat mycobacterial infections. Relieving stromal pathologies offers a novel strategy for treating tuberculosis by enhancing host immunity.
Area of Science:
- Immunology
- Microbiology
- Pathology
Background:
- Pathogenic mycobacteria excel at intracellular survival within macrophages.
- Granulomas form as a host response but create niches that promote pathogen survival and antibiotic resistance.
- Current treatments often struggle against mycobacteria residing within granulomas.
Purpose of the Study:
- To review innovative research on host-directed therapies (HDTs) for mycobacterial infections.
- To highlight the role of granuloma stroma as a primary driver of infection.
- To summarize advances in targeting host vasculature, hemostasis, and extracellular matrix.
Main Methods:
- Review of preclinical and clinical studies on HDTs.
- Analysis of research on host-pathogen interactions within granulomas.
- Exploration of host-pathogen co-evolutionary dynamics.
Main Results:
- 'Secondary' symptoms in the granuloma stroma are identified as primary drivers of infection.
- Relieving stromal pathologies with HDTs benefits the host by restoring immunity.
- HDTs offer a strategy independent of pathogen antimicrobial resistance.
Conclusions:
- Targeting granuloma stromal pathologies represents a promising host-directed approach.
- Understanding host-pathogen interactions in the stroma is crucial for developing effective HDTs.
- HDTs against stromal targets show potential in preclinical and clinical settings for tuberculosis treatment.
More Related Videos
10:10A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
Published on: October 5, 2015
07:42A Novel Microdissection Approach to Recovering Mycobacterium tuberculosis Specific Transcripts from Formalin Fixed Paraffin Embedded Lung Granulomas
Published on: June 5, 2014
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tumor Immunotherapy